An organometallic compound represented by Formula 1, an organic light-emitting device including the organometallic compound, and a diagnostic composition including the organometallic compound:

M(L.sub.1).sub.n1(L.sub.2).sub.n2,Formula 1 wherein, in Formula 1, M, L.sub.1, L.sub.2, n1, and n2 are each independently the same as described herein.

A flow battery includes a first liquid containing a first electrode mediator dissolved therein, a first electrode immersed in the first liquid, a first active material immersed in the first liquid, and a first circulation mechanism that circulates the first liquid between the first electrode and the first active material, wherein the first electrode mediator includes a tetrathiafulvalene derivative, and the tetrathiafulvalene derivative has a ring-forming substituent at positions 4,4 and 5,5 of a tetrathiafulvalene skeleton thereof.

Provided are mucolytic compounds that are more effective, and/or absorbed less rapidly from mucosal surfaces, and/or are better tolerated as compared to N-acetylcysteine (NAC) and DTT. The compounds are represented by compounds of Formula I which embrace structures (Ia)-(Ib): ##STR00001##
where the structural variables are as defined herein.

Provided are mucolytic compounds that are more effective, and/or absorbed less rapidly from mucosal surfaces, and/or are better tolerated as compared to N-acetylcysteine (NAC) and DTT. The compounds are represented by compounds of Formula I which embrace structures (Ia)-(Ib): ##STR00001##
where the structural variables are as defined herein.

The invention relates to methods of treating cell proliferative disorders. The invention further relates to pharmaceutical compositions for treating cell proliferative disorders, especially cancer.

The invention relates to methods of treating cell proliferative disorders. The invention further relates to pharmaceutical compositions for treating cell proliferative disorders, especially cancer.

The present invention includes novel compounds containing heterocycles or azaheterocycles and fused phenylene or aza and cyano substituted variants thereof. These compounds may be useful as host materials for phosphorescent electroluminescent devices.

The invention relates to a process for the manufacture of a cyclic oligo(arylene ether) which can be a cyclic oligo(dichloromethylene arylene ether) or a cyclic oligo(arylene ether ketone); the process comprises the step of causing an aromatic compound to react with a hexachloroxylene compound in a pseudo-high dilution environment. The invention relates also to new cyclic oligo(arylene ether)s and their use for the manufacture of acyclic poly (arylene ether)s, such as PEKK, by ring-opening polymerization.

The present invention relates to compounds containing fused dibenzo more-than-six-membered heterocycles or azaheterocycles. These compounds may be useful as host materials for phosphorescent electroluminescent devices.

This invention relates to a compound comprising a structure of formula (I): cyclic disulfide moiety-phosphorus coupling group (I). The cyclic disulfide moiety has the structure of (C-I), (C-II), or (C-III). This invention also relates to an oligonucleotide comprising one or more compounds that comprise the structure of formula (I), wherein at least one phosphorus coupling group contains a nucleoside or oligonucleotide. The invention also relates to a pharmaceutical composition comprising the oligonucleotide described herein and a method of reducing or inhibiting the expression of a target gene by administering to the subject a therapeutically effective amount of the oligonucleotide described herein.

##STR00001##